

Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

Vedolizumab (Entyvio®)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- Adult patients with moderately to severely active ulcerative colitis (UC).
- Adult patients with moderately to severely active Crohn's disease (CD).

Compendial Uses

- Immune checkpoint inhibitor-related toxicity
- Acute graft versus host disease

All other indications are considered experimental/investigational and not medically necessary.

DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

Ulcerative Colitis (UC) and Crohn's Disease (CD)

Continuation requests: Chart notes or medical record documentation supporting positive clinical response to therapy or remission.

Immune Checkpoint Inhibitor-related Toxicity and Acute Graft versus Host Disease

Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

PRESCRIBER SPECIALTIES

The medication must be prescribed by or in consultation with one of the following:

- Crohn's disease and ulcerative colitis: gastroenterologist
- Immune checkpoint inhibitor-related toxicity: gastroenterologist, hematologist, or oncologist

Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

- Acute graft versus host disease: hematologist or oncologist

COVERAGE CRITERIA

Ulcerative Colitis (UC)

Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.

Crohn's Disease (CD)

Authorization of 12 months may be granted for treatment of moderately to severely active Crohn's disease.

Immune Checkpoint Inhibitor-related Toxicity

Authorization of 6 months may be granted for the treatment of immune checkpoint inhibitor-related diarrhea or colitis when the member has experienced an inadequate response, intolerance, or contradiction to systemic corticosteroids or infliximab.

Acute Graft versus Host Disease

Authorization of 12 months may be granted for treatment of acute graft versus host disease when either of the following criteria is met:

- Member has had an inadequate response to systemic corticosteroids.
- Member has an intolerance or contraindication to corticosteroids.

CONTINUATION OF THERAPY

Ulcerative Colitis (UC)

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

- Stool frequency
- Rectal bleeding
- Urgency of defecation
- C-reactive protein (CRP)
- Fecal calprotectin (FC)
- Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
- Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo score)

Crohn's Disease (CD)

Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active Crohn's disease and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active Crohn's disease and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

- Abdominal pain or tenderness
- Diarrhea
- Body weight
- Abdominal mass
- Hematocrit
- Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
- Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score)

Immune Checkpoint Inhibitor-related Toxicity and Acute Graft versus Host Disease

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria.

OTHER

For all indications: Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug.

DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

MEDICATION QUANTITY LIMITS

| Drug Name | Diagnosis | Maximum Dosing Regimen |
|-----------------------|--|--|
| Entyvio (Vedolizumab) | Acute Graft Versus Host Disease | Route of Administration: Intravenous 300mg on weeks 0, 2, and 6, then every 8 weeks |
| Entyvio (Vedolizumab) | Crohn's Disease | Route of Administration: Intravenous ≥18 Year(s) Initial: 300mg on weeks 0, 2, and 6 Maintenance: 300mg every 8 weeks |
| Entyvio (Vedolizumab) | Immune Checkpoint Inhibitor-Related Toxicity | Route of Administration: Intravenous 300mg on weeks 0, 2, and 6, then every 8 weeks |
| Entyvio (Vedolizumab) | Ulcerative Colitis | Route of Administration: Intravenous ≥18 Year(s) Initial: 300mg on weeks 0, 2, and 6 Maintenance: 300mg every 8 weeks |



Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Entyvio [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; May 2024.
2. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. *Am J Gastroenterol*. 2011;106(Suppl 1):S2-S25.
3. Lichtenstein GR, Loftus Jr EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113:481-517.
4. Rubin DT, Ananthakrishnan AN, et al. 2019 ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2019;114:384-413.
5. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed January 22, 2025.
6. NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®). Management of Immunotherapy-Related Toxicities. Version 1.2025. Available at: www.nccn.org. Accessed January 22, 2025.
7. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Guideline Update. *J Clin Oncol*. 2021; 39(36):4073-4126.
8. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*. 2020; 158:1450-1461.
9. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. 2021; 160: 2496-2508.
10. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.
11. NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®). Hematopoietic Cell Transplantation (HCT). Version 2.2024. Available at: www.nccn.org. Accessed January 22, 2025.

EFFECTIVE DATE

| | |
|-----------|---|
| 6/11/2014 | (6/11/14 - Approved and implemented via executive decision) |
| 4/25/2015 | (3/25/15 - Approved and implemented via executive decision) |
| 8/17/2016 | (8/17/16 - Annual P&T Committee Review) |
| 12/1/2016 | (12/1/16 - Approved and implemented via executive decision) |
| 2/27/2018 | (2/27/18 - Annual P&T Committee Review) |



BlueCross BlueShield
of Tennessee

Policy

Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

| | |
|------------|---|
| 10/1/2018 | (9/11/18 - Approved by P&T Corporate Subcommittee) |
| 10/9/2018 | (10/9/18 - Approved by P&T Corporate Subcommittee) |
| 12/11/2018 | (12/11/18 - Maintenance / P&T Corporate Subcommittee) |
| 10/8/2019 | (10/8/19 - Maintenance / P&T Corporate Subcommittee) |
| 4/1/2020 | (1/14/20 - Approved by P&T Corporate Subcommittee) |
| 3/2/2021 | (12/8/20 - Approved by P&T Corporate Subcommittee) |
| 3/2/2022 | (12/14/21 – Approved by P&T Corporate Subcommittee) |
| 8/30/2022 | (6/14/22 - Approved by P&T Corporate Subcommittee) |
| 1/1/2024 | (10/10/23 - CHS - Approved by P&T Corporate Subcommittee) |
| 4/1/2024 | (3/12/24 –Maintenance CHS Dosing/ Approved by P&T Corporate Subcommittee) |
| 10/31/2024 | (8/13/24 - Approved by P&T Corporate Subcommittee) |
| 7/31/2025 | (5/13/25 - Approved by P&T Corporate Subcommittee) |
| 4/30/2026 | (2/10/26 - Approved by P&T Corporate Subcommittee) |

ID_CHS